COMMUNIQUÉS West-GlobeNewswire

Tango Therapeutics Appoints Robert Azelby to Board of Directors
22/06/2026
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today [...]
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
22/06/2026
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other [...]
Pioneering screening test offers potential to find more aggressive prostate cancers
22/06/2026
Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer STOCKHOLM, June 22, 2026 (GLOBE NEWSWIRE) -- A3P Biomedical, a diagnostics [...]
Transactions of Managers and Closely Associated Persons
23/06/2026
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 10,133,333 [...]
uniQure Announces $150 Million Proposed Public Offering
22/06/2026
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
22/06/2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
MoonLake Immunotherapeutics Announces Proposed Public Offering
22/06/2026
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today [...]
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
22/06/2026
Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access to Management [...]
IMUNON to Present at the Life Sciences Investor Forum on June 25th
22/06/2026
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., [...]
NADP and AADOM announce partnership
22/06/2026
Joint initiative will address dental office pain points with dental benefits DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- The American Association of Dental Office Management (AADOM) and the National Association of Dental [...]
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
22/06/2026
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation - NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
22/06/2026
Company announcement – No. 27 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June [...]
Ozari Health Releases 2026 Online GLP-1 Provider Checklist
22/06/2026
LegitScript-verified New York-based telehealth platform outlines how patients can compare online GLP-1 providers, including Semaglutide starting at $86 per month and Tirzepatide starting at $120 per month. New York, NY [...]
Genista Launches Refreshed Brand and Website, Positioning Itself as the Operating System for Product Safety
22/06/2026
The rebrand reflects the company’s evolution from testing laboratory to integrated platform — unifying accredited science, intelligent software, and robotics-enabled automation into one closed loop SAN JOSE, Calif., [...]
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
22/06/2026
Company announcement No. 26 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 25, 2026) Copenhagen, Denmark, June 22, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
22/06/2026
Cumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners. Multi-year agreements extending up to 10 years provide recurring [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026
22/06/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 15 juin au 19 juin 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
22/06/2026
Aggregated presentation by day and by market Purchases of own shares from June 15th to June 19th 2026 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with [...]

Pages